Friendly A positive Widal result does not reliably confirm typhoid because antibodies can reflect previous exposure or ...
FDA approves Hibsago (bepirovirsen) with NrtI therapy for adult chronic hepatitis B without cirrhosis; phase 3 trials show up to 20% functional cure at 72 weeks.
In its own approval announcement on Oct. 20, the FDA hailed Hibsago as a “first-of-its-kind” treatment in chronic hepatitis B ...
The FDA approved Hibsago (bepirovirsen; GSK), the first antisense oligonucleotide for chronic hepatitis B, for use with a nucleos (t)ide analogue in adults without cirrhosis, the agency announced ...
GSK’s bepirovirsen (Hibsago) has secured FDA approval for the treatment of chronic hepatitis B virus (HBV), when used with existing antiviral therapy in adults without cirrhosis. “This is the start of ...
The FDA approved bepirovirsen, the first antisense oligonucleotide for chronic hepatitis B, offering a new treatment with functional cure potential. Bepirovirsen is specifically approved for patients ...
The FDA approved bepirovirsen as the first antisense oligonucleotide for chronic hepatitis B virus infection, alongside existing antiviral therapy for eligible adults without cirrhosis. Bepirovirsen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results